Logo image of GLTO

GALECTO INC (GLTO) Stock Fundamental Analysis

NASDAQ:GLTO - Nasdaq - US36322Q2066 - Common Stock - Currency: USD

3.37  0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GLTO. GLTO was compared to 549 industry peers in the Biotechnology industry. The financial health of GLTO is average, but there are quite some concerns on its profitability. GLTO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GLTO has reported negative net income.
In the past year GLTO has reported a negative cash flow from operations.
GLTO had negative earnings in each of the past 5 years.
GLTO had a negative operating cash flow in each of the past 5 years.
GLTO Yearly Net Income VS EBIT VS OCF VS FCFGLTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -121.20%, GLTO is not doing good in the industry: 79.23% of the companies in the same industry are doing better.
GLTO's Return On Equity of -151.50% is on the low side compared to the rest of the industry. GLTO is outperformed by 62.66% of its industry peers.
Industry RankSector Rank
ROA -121.2%
ROE -151.5%
ROIC N/A
ROA(3y)-103.21%
ROA(5y)-74.46%
ROE(3y)-117.92%
ROE(5y)-83.79%
ROIC(3y)N/A
ROIC(5y)N/A
GLTO Yearly ROA, ROE, ROICGLTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GLTO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLTO Yearly Profit, Operating, Gross MarginsGLTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

GLTO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GLTO has less shares outstanding
GLTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLTO Yearly Shares OutstandingGLTO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
GLTO Yearly Total Debt VS Total AssetsGLTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

GLTO has an Altman-Z score of -30.13. This is a bad value and indicates that GLTO is not financially healthy and even has some risk of bankruptcy.
GLTO's Altman-Z score of -30.13 is on the low side compared to the rest of the industry. GLTO is outperformed by 87.61% of its industry peers.
There is no outstanding debt for GLTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -30.13
ROIC/WACCN/A
WACCN/A
GLTO Yearly LT Debt VS Equity VS FCFGLTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 4.96 indicates that GLTO has no problem at all paying its short term obligations.
GLTO's Current ratio of 4.96 is in line compared to the rest of the industry. GLTO outperforms 54.28% of its industry peers.
A Quick Ratio of 4.96 indicates that GLTO has no problem at all paying its short term obligations.
GLTO has a Quick ratio of 4.96. This is comparable to the rest of the industry: GLTO outperforms 55.74% of its industry peers.
Industry RankSector Rank
Current Ratio 4.96
Quick Ratio 4.96
GLTO Yearly Current Assets VS Current LiabilitesGLTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 51.73% over the past year.
EPS 1Y (TTM)51.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GLTO will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.23% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y36.03%
EPS Next 2Y35.27%
EPS Next 3Y22.93%
EPS Next 5Y15.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLTO Yearly Revenue VS EstimatesGLTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2030 5M 10M 15M 20M 25M
GLTO Yearly EPS VS EstimatesGLTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GLTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GLTO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLTO Price Earnings VS Forward Price EarningsGLTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLTO Per share dataGLTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as GLTO's earnings are expected to grow with 22.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.27%
EPS Next 3Y22.93%

More info and screens

0

5. Dividend

5.1 Amount

GLTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALECTO INC

NASDAQ:GLTO (8/19/2025, 4:30:01 PM)

3.37

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)10-30 2025-10-30
Inst Owners14.52%
Inst Owner Change-6.83%
Ins Owners3.69%
Ins Owner Change0.05%
Market Cap4.45M
Analysts43.33
Price Target6.12 (81.6%)
Short Float %2.15%
Short Ratio1.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-25%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)23.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-17.62
EYN/A
EPS(NY)-3
Fwd EYN/A
FCF(TTM)-10.05
FCFYN/A
OCF(TTM)-10.05
OCFYN/A
SpS0
BVpS8.3
TBVpS8.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -121.2%
ROE -151.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.21%
ROA(5y)-74.46%
ROE(3y)-117.92%
ROE(5y)-83.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.96
Quick Ratio 4.96
Altman-Z -30.13
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.19%
EPS Next Y36.03%
EPS Next 2Y35.27%
EPS Next 3Y22.93%
EPS Next 5Y15.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-223.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y65.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.34%
OCF growth 3YN/A
OCF growth 5YN/A